The Importance of Cervical Cancer Screening in the U.S.

What this episode covers

Chris Beddard, VP of US Marketing at BD, discusses the BD Onclarity HPV assay, an FDA-approved diagnostic tool featuring extended genotyping to help clinicians manage cervical cancer risk. She explains the rigorous development process, including multi-year clinical trials for three testing paradigms, and highlights the significant drop in screening during the pandemic. Beddard emphasizes the importance of market shaping, reimbursement alignment, and global health initiatives, particularly in Africa, to ensure patients receive timely and precise care.